BMEA

Announcements

Nothing here yet

Daily updates

• Biomea Fusion Reports Phase 1 Weight-Loss Data for Oral GLP-1 Candidate BMF-650Oct 14, 2026
• Biomea Fusion Reports Phase 1 Weight-Loss Results for Oral GLP-1 Agonist BMF-650Oct 14, 2026
• Biomea Fusion completed enrollment in Phase 2 COVALENT-211 trialAug 24, 2026

FDA designations

Nothing here yet

News

• Biomea Fusion announces Phase 1 results for BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonistOct 14, 2026
• Biomea Fusion plans to announce Phase 1 results for BMF-650, its next-generation oral small-molecule GLP-1 receptor agonistOct 12, 2026
• Biomea Fusion completed enrollment in the Phase 2 COVALENT-211 trial of icovamenib in insulin-deficient type 2 diabetesAug 24, 2026
• Biomea Fusion dosed the first patient in the OPAL study evaluating icovamenib combined with semaglutide for obesityAug 13, 2026
• Biomea Fusion reported positive 52-week Phase 2 results showing improved C-peptide and durable benefit with Icovamenib in type 1 diabetesApr 28, 2026